EDAP TMS S.A. (EDAP) Q2 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 76.8% increase in HIFU revenue and improved gross margins. Despite operating and net losses, strategic investments in HIFU and efficient inventory management are promising. Positive Q&A insights include efforts to improve reimbursement, growing demand, and multiunit purchases, indicating confidence in future growth. However, some concerns remain about reimbursement and unclear management responses. Overall, the company's strategic focus and optimistic guidance point to a positive stock price movement.
Key Financial Performance
Global HIFU Revenues USD 9.7 million, up 89% year-over-year. This increase was driven by the net placement of 12 Focal One systems, representing a year-over-year growth of 140%.
Total Revenue EUR 16 million, an increase of 1.6% year-over-year. The increase was driven by significant strength in the core HIFU business, which grew 76.8% over the second quarter of 2024, offset by a decline in noncore distribution and ESWL businesses by 31.2%.
Total HIFU Revenue EUR 8.5 million, up 76.8% year-over-year. This was driven by 9 Focal One capital sales in Q2 2025 versus 3 in the prior year and a 16.1% year-over-year increase in Focal One treatment-driven revenue.
Gross Profit EUR 6.8 million, up from EUR 5.9 million year-over-year. Gross margin increased to 42.5% from 37.5%, primarily due to the strategic focus on the high-margin HIFU business segment.
Operating Expenses EUR 12.6 million, up from EUR 12.1 million year-over-year. The increase was primarily due to focused investments in the HIFU business.
Operating Loss EUR 5.8 million, compared to EUR 6.1 million year-over-year. Excluding noncash share-based compensation, the operating loss would have been EUR 5.3 million.
Net Loss EUR 5.6 million or EUR 0.15 per share, compared to EUR 6.1 million or EUR 0.16 per share year-over-year.
Inventory EUR 15.5 million, down from EUR 18 million at the end of Q1 2025. The decrease was due to efficient just-in-time inventory management and higher inventory turnover due to increased demand for Focal One.
Cash and Cash Equivalents EUR 16.3 million, down from EUR 22.8 million at the end of Q1 2025. The decrease was driven by cash used in operating activities to support strategic investment in HIFU.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Focal One HIFU: Global HIFU revenues reached USD 9.7 million, up 89% YoY. 12 Focal One systems were placed, including 9 capital sales and 4 operating leases. The new Focal One i system was introduced, featuring advanced imaging and robotic capabilities. The first Focal One i system was delivered in the U.S. and has successfully performed procedures.
Endometriosis Application: Received CE marking for HIFU use in rectal endometriosis. Initial commercialization in Europe has begun. Clinical studies show HIFU provides similar pain relief as surgery but with fewer complications and shorter recovery times.
Market Expansion: Focal One systems were adopted by major hospital networks, including Cleveland Clinic facilities worldwide. Expansion into endometriosis treatment opens a new patient population.
Operational Efficiencies: Inventory decreased to EUR 15.5 million due to just-in-time inventory management and higher turnover. Gross margin improved to 42.5% in Q2 2025 from 37.5% in Q2 2024.
Strategic Financing: Entered into a letter of intent for a EUR 36 million (USD 42 million) financing facility with the European Investment Bank to support HIFU expansion and new clinical developments.
Transition to U.S. Domestic Filer: Announced transition to U.S. domestic filer status starting January 1, 2026, to align with SEC and NASDAQ requirements, aiming to attract institutional investors.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Advantage Plan Challenges: Intermittent challenges with certain healthcare plan providers, particularly Medicare Advantage plans, have impacted growth in certain markets and the adoption of HIFU. This has necessitated efforts to accelerate pre-authorizations for procedures.
Tariff Impact: A 15% tariff impact on goods transferred between France and the U.S. is forecasted, which could affect cost structures and profitability.
Decline in Noncore Businesses: The noncore ESWL and distribution businesses are expected to decline by 25% to 30% year-over-year, which could offset growth in the core HIFU business.
Inventory and Cash Flow Management: Decreased inventory levels and cash reserves due to strategic investments in HIFU, which may strain liquidity and operational flexibility.
Regulatory and Reimbursement Risks: While there is positive news on reimbursement rates, the reliance on CMS and other regulatory bodies for favorable reimbursement policies poses a risk if these policies change.
Strategic Execution Risks: The company is undergoing significant strategic transitions, including becoming a U.S. domestic filer and expanding into new applications like endometriosis, which could strain resources and execution capabilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core HIFU business revenue growth: Expected to grow within the range of 26% to 34% year-over-year in 2025.
Noncore ESWL and distribution business revenue decline: Expected to decline within the range of 25% to 30% year-over-year in 2025.
CMS proposed hospital payment for Focal One HIFU procedure in 2026: Set at $9,765, representing an increase of $518 or 5.6% compared to 2025.
CMS proposed physician reimbursement for Focal One HIFU procedure in 2026: Proposed at 26.43 total RVUs, translating to a Medicare payment of $888.
New CPT code for BPH treatment with HIFU: Effective July 1, 2025, enabling facilities to be reimbursed for investigational studies in BPH.
Strategic financing facility with European Investment Bank: EUR 36 million (approximately USD 42 million) to support Focal One expansion and new clinical indications.
Transition to U.S. domestic filer: Effective January 1, 2026, aligning with U.S. SEC reporting rules and NASDAQ requirements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What efforts are being taken to improve the reimbursement situation for HIFU procedures?
A:Efforts include strong collaboration with market access partners to accelerate pre-authorizations for Focal One procedures, dissemination of clinical evidence from the HIFI and FARP studies to bolster payer confidence, and increased training for new urologists. Early signs of improvement are emerging with more approvals for individual procedures.
Q:What is the reason for the deceleration in HIFU procedure growth from 30%+ to mid-single digits?
A:The deceleration is attributed to regional Medicare Advantage issues, which are being addressed. There is also an increase in urologists seeking training on the technology, and quarter-over-quarter and year-over-year growth has been observed.
Q:What factors does CMS consider when determining reimbursement rates?
A:CMS considers factors such as cost of service, clinical value, volume of procedures and treatments, billing data, and incidental factors like malpractice insurance costs. HIFU's clinical value and data have been recognized, contributing to proposed reimbursement rate increases.
Q:How much effort is being placed on multiunit purchases by the commercial team?
A:Considerable effort is placed on multiunit purchases. Three regional integrated hospital systems acquired their second Focal One system in Q2, indicating strong validation of the technology's value. The commercial team focuses on kicking off original programs, which lead to additional system sales.
Q:Does the CMS provide reimbursement for BPH indications, and what is the company's approach to this?
A:CMS does not currently provide a defined indication for BPH. The company is conducting a combined Phase I/II study in France and is in discussions with U.S. academic partners to initiate a U.S. clinical study by early 2026. The goal is to further develop procedures and clinical evidence for BPH.
Q:What is the update on the endometriosis trial?
A:The Phase III double-blinded study showed that over 80% of sham arm patients chose Focal One treatment after unblinding. A limited European launch is underway following the CE mark approval in March. The Focal One i platform has new features tailored for endometriosis, and studies are comparing HIFU therapy to surgery.
Q:How are the EUR 36 million funds from the letter of intent being earmarked?
A:No funds have been received yet. Once finalized, the funds will be targeted for accelerated commercial growth, clinical indications, and new technologies within the HIFU ecosystem.
Q:Is Q2 an inflection point for Focal One sales, and what is the confidence level for future growth?
A:Management believes Q2 is an inflection point due to a strong pipeline, increased commercial headcount, and growing demand for focal therapy in prostate cancer. They expect continued growth, supported by reimbursement and strategic capital investments.
Q:What is the status of the U.S. procedure volume and its impact on capital sales?
A:Denials and appeals are being addressed regionally, with improvements seen. Hospitals are armed with updated clinical data, and there is no impact on capital sales. The company continues to see projected growth and strong engagement from academic centers.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the current backlog size and its comparison to previous periods, using vague terms like 'stronger' and 'qualified active pipeline.' Additionally, they did not provide a clear timeline for when the EUR 36 million funds would be received or detailed allocation plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BPH
CMS
Cleveland Clinic
EDAP
EUR increase
EUR loss
EUR month
EUR period
EUR share
European Investment
HIFU EUR
Health
IRE
Investment Bank
LLC Research
RVUs
Research Division
USD
application
capital sale
code
commercialization
energy delivery
facility European
fee
filer
financing facility
loss EUR
month EUR
payment
physician
potential
practice
prostate ablation
rule
surgery
ultrasound
EDAP Transcript
EDAP TMS S.A. (EDAP) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call lacked forward-looking statements and strategic initiatives, providing no guidance or market trends, which is typically negative. However, the company reported strong financial performance with increased revenue, gross margin, and net income. The absence of negative Q&A insights further stabilizes the outlook. Without a market cap, we assume a moderate response, resulting in a neutral sentiment.
EDAP TMS S.A. (EDAP) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call highlights strong financial performance with a 12% revenue increase, improved gross margins, and a 40% rise in net income. Despite regulatory compliance risks, the financial metrics are robust, indicating positive market sentiment. The absence of strategic updates or operational concerns further supports a positive outlook.
EDAP TMS S.A. (EDAP) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reflects strong growth in the core HIFU business, with record revenue and significant increases in HIFU revenue and placements. The strategic financing with EIB and the new CPT code for BPH treatment are positive developments. Although there are concerns about the declining noncore business and operating losses, the optimistic guidance and strategic investments in HIFU suggest a positive outlook. The Q&A session confirmed positive trends in U.S. procedures and payer coverage. Overall, these factors indicate a likely positive stock price movement.
EDAP TMS S.A. (EDAP) Q2 2025 Earnings Conference Call Transcript
Positive8-28
The earnings call reveals strong financial performance with a 76.8% increase in HIFU revenue and improved gross margins. Despite operating and net losses, strategic investments in HIFU and efficient inventory management are promising. Positive Q&A insights include efforts to improve reimbursement, growing demand, and multiunit purchases, indicating confidence in future growth. However, some concerns remain about reimbursement and unclear management responses. Overall, the company's strategic focus and optimistic guidance point to a positive stock price movement.
EDAP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
